A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh

CompletedOBSERVATIONAL
Enrollment

116

Participants

Timeline

Start Date

May 2, 2020

Primary Completion Date

June 5, 2020

Study Completion Date

June 5, 2020

Conditions
IvermectinHydroxychloroquineCOVID19
Interventions
DRUG

Ivermectin + Doxycycline

SARS-CoV-2 infection was confirmed by RT PCR in every case. For group A, Ivermectin 200mcg/kg single dose and Doxycycline 100mg BID for 10 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 3rd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.

DRUG

Hydroxychloroquine + Azithromycin

SARS-CoV-2 infection was confirmed by RT PCR in every case. For group B, Hydroxychloroquine 400mg first day then 200mg BID + Azithromycin 500mg BID for 5 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 2nd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.

Trial Locations (1)

4741

Chakoria Upazilla Health Complex, Cox’s Bāzār

All Listed Sponsors
lead

Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar

OTHER_GOV

NCT04434144 - A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh | Biotech Hunter | Biotech Hunter